-
Mashup Score: 1Vaccinating against cancer: getting to prime time - 11 month(s) ago
Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell engagers, have fundamentally changed our approach to treating cancer. However, successes with cancer vaccines have been more difficult to realize. While vaccines against specific viruses have been widely adopted to prevent the development of cancer, only two vaccines can improve survival in advanced disease:…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0132 Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers - 12 month(s) ago
Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of a tumor, is routinely used as a predictive biomarker for immunotherapy response in metastatic cancer patients. Sequencing of paired tumor and normal specimens allows for correction of TMB estimates with patient-specific germline variants. For tumor only assays, TMB estimates are corrected using…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Racial differences in TMB measures b/w paired tumor/normal & tumor-only sequencing across endometrial, bladder & non-small cell lung cancers [Nov 7, 2022] @ribozyme et al. @JITC #SITC22 Abs 132 https://t.co/1g4yPP91uq #PrecisionMedicine #ImmunoOnc #gyncsm #blcsm @lcsm @TempusLabs
-
-
Mashup Score: 0132 Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers - 12 month(s) ago
Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of a tumor, is routinely used as a predictive biomarker for immunotherapy response in metastatic cancer patients. Sequencing of paired tumor and normal specimens allows for correction of TMB estimates with patient-specific germline variants. For tumor only assays, TMB estimates are corrected using…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Racial differences in TMB measures b/w paired tumor/normal & tumor-only sequencing across endometrial, bladder & non-small cell lung cancers [Nov 7, 2022] @ribozyme et al. @JITC #SITC22 Abs 132 https://t.co/1g4yPP9zjY #PrecisionMedicine #ImmunoOnc #gyncsm #blcsm @lcsm @TempusLabs
-
-
Mashup Score: 2Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs - 1 year(s) ago
With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment settings is increasing rapidly. Although some patients will experience durable benefit, many have either no clinical response or see their disease progress…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Addressing Resistance to PD-1/PD-(L)1 Pathway Inhibition: Considerations for Combinatorial Clinical Trial Designs https://t.co/SBfzHmUjtT https://t.co/wK8UUauwd0
-
-
Mashup Score: 8
With the advent of immunotherapeutic agents, durable and dramatic responses have been observed in several hard-to-treat malignancies, outlining a roadmap to conquering cancer. Immune checkpoint inhibitors (ICPi) are a class of immunotherapeutic agents that attack the tumor cells by reinvigorating the suppressed immune system. However, the unbridled T-cell activity disrupts the immune homeostasis…
Categories: Latest Headlines, Oncologists2Tweet-
RT @LabNaing: Strategies for improving the management of immune-related adverse events https://t.co/hj9gY1Mr69 by @ANaingMD, @HajjarJoud @g…
-
-
Mashup Score: 0BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma - 1 year(s) ago
Plasmablastic lymphoma (PBL) is a rare subtype of aggressive large B-cell lymphoma, with a dismal prognosis despite aggressive therapies. New approaches are needed for those with refractory disease. PBL expresses antigens similar to multiple myeloma (MM), including B-cell maturation antigen (BCMA). Chimeric antigen receptor T-cell (CAR-T) therapy directed against BCMA has shown efficacy for the…
Categories: Hem/Oncs, Latest HeadlinesTweet-
I've always wondered about #lymsm - #MMsm overlap cases like this... good to see that BCMA CAR-T works! @jitcancer case report of cilta-cel (single-pt IND) for relapsed B-ALL (s/p allo) ➡️ PBL. Cells only variably BCMA+ by IHC, but cilta-cel succeeded! https://t.co/hTk5eXbNJu
-
-
Mashup Score: 1
Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of a tumor, is routinely used as a predictive biomarker for immunotherapy response in metastatic cancer patients. Sequencing of paired tumor and normal specimens allows for correction of TMB estimates with patient-specific germline variants. For tumor only assays, TMB estimates are corrected using…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Racial differences in TMB measures b/w paired tumor/normal & tumor-only sequencing across endometrial, bladder & non-small cell lung cancers [Nov 7, 2022] @ribozyme et al. @JITC #SITC22 Abs 132 https://t.co/1g4yPP91uq #PrecisionMedicine #ImmunoOnc #gyncsm #blcsm @lcsm @TempusLabs
-
-
Mashup Score: 2Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma - 1 year(s) ago
Introduction In clear cell renal cell carcinoma (ccRCC), tumor-associated macrophage (TAM) induction of CD8+T cells into a terminally exhausted state has been implicated as a major mechanism of immunotherapy resistance, but a deeper biological understanding is necessary. Methods Primary ccRCC tumor samples were obtained from 97 patients between 2004 and 2018. Multiplex immunofluorescence using…
Categories: General Medicine News, Latest HeadlinesTweet-
Spatial patterns of #immunecells predict patient outcomes in clear cell #renalcellcarcinoma https://t.co/Dc5T6GeSRI https://t.co/aCsZkg4evg
-
-
Mashup Score: 1Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy - 1 year(s) ago
Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of relapsed/refractory hematological malignancies. Using CAR-T cell therapy, a high percentage of patients respond initially, yet up to 60% of patients eventually relapse. Predictive and prognostic factors allowing to predict
Categories: Hem/Oncs, Latest HeadlinesTweet-
A letter to @jitcancer by @anna_mclaughl to address the importance of quality control when computational models are used for T cell therapy. In a world of @chatgptandai we need to temper our predictive aspirations w empiric validation and scientific rigor https://t.co/rU8EjSSpFJ
-
-
Mashup Score: 0An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer - 1 year(s) ago
Background Emerging evidence suggests that the mechanism of chemotherapy-induced cell death may influence the antitumor immune response in patients with cancer. Unlike immunologically silent apoptosis, pyroptosis is a lytic and inflammatory form of programmed cell death characterized by pore formation in the cell membrane and release of proinflammatory factors. Gasdermin E (GSDME) has recently…
Categories: Hem/Oncs, Latest HeadlinesTweet-
How do antibody drug conjugates exert their anti-tumor effect? Certainly, direct delivery of the payload (and bystander effect). But this report @jitcancer on an anti-mesothelin ADC shows they can induce pyroptosis and trigger antitumor immunity as well. https://t.co/pdFJ4RpZC5
-
Delighted to participate with Drs. Larry Fong and Ryan Chang on this @jitcancer review. Check it out! 👉Vaccinating against cancer: getting to prime time https://t.co/eS14lJluWB